ATE539755T1 - Verwendung von selektiven chloridkanalmodulatoren zur behandlung des alkohol- und/oder stimulans missbrauches - Google Patents

Verwendung von selektiven chloridkanalmodulatoren zur behandlung des alkohol- und/oder stimulans missbrauches

Info

Publication number
ATE539755T1
ATE539755T1 AT06740763T AT06740763T ATE539755T1 AT E539755 T1 ATE539755 T1 AT E539755T1 AT 06740763 T AT06740763 T AT 06740763T AT 06740763 T AT06740763 T AT 06740763T AT E539755 T1 ATE539755 T1 AT E539755T1
Authority
AT
Austria
Prior art keywords
alcohol
chloride channel
relates
treatment
channel modulators
Prior art date
Application number
AT06740763T
Other languages
German (de)
English (en)
Inventor
Sanjay Sabnani
Ibanez Juan Jose Legarda
Original Assignee
Catasys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catasys Inc filed Critical Catasys Inc
Application granted granted Critical
Publication of ATE539755T1 publication Critical patent/ATE539755T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06740763T 2005-04-21 2006-04-07 Verwendung von selektiven chloridkanalmodulatoren zur behandlung des alkohol- und/oder stimulans missbrauches ATE539755T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/111,435 US20050192271A1 (en) 2003-07-15 2005-04-21 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
PCT/US2006/013155 WO2006115743A2 (en) 2005-04-21 2006-04-07 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse

Publications (1)

Publication Number Publication Date
ATE539755T1 true ATE539755T1 (de) 2012-01-15

Family

ID=37215204

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06740763T ATE539755T1 (de) 2005-04-21 2006-04-07 Verwendung von selektiven chloridkanalmodulatoren zur behandlung des alkohol- und/oder stimulans missbrauches

Country Status (17)

Country Link
US (3) US20050192271A1 (https=)
EP (1) EP1742639B1 (https=)
JP (1) JP2008536921A (https=)
KR (1) KR20080004615A (https=)
CN (1) CN101203225A (https=)
AT (1) ATE539755T1 (https=)
AU (1) AU2006240324B2 (https=)
BR (1) BRPI0610038A2 (https=)
CA (1) CA2605918A1 (https=)
CR (1) CR9444A (https=)
IL (1) IL186641A0 (https=)
MX (1) MX2007012993A (https=)
NO (1) NO20075562L (https=)
NZ (1) NZ562585A (https=)
RU (1) RU2007143053A (https=)
WO (1) WO2006115743A2 (https=)
ZA (1) ZA200709048B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
RU2468799C1 (ru) * 2011-08-03 2012-12-10 Общество с ограниченной ответственностью "Урал Крафт" Способ купирования алкогольного абстинентного синдрома посредством блокады бензодиазепиновых рецепторов
WO2015054730A1 (en) * 2013-10-14 2015-04-23 Palmaya Pty Ltd Compositions and methods of administering same
US20200143922A1 (en) * 2016-06-03 2020-05-07 Yale University Methods and apparatus for predicting depression treatment outcomes
JP2021521103A (ja) * 2018-04-06 2021-08-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 物質使用障害の処置におけるガボキサドールの使用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028611A (en) * 1989-06-29 1991-07-02 The Regents Of The University Of Minnesota Treatment for cocaine use
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
DE4123106A1 (de) * 1991-07-09 1993-01-14 Schering Ag Arzneimittel zur behandlung von entzugssymptomen
US5229120A (en) * 1992-02-05 1993-07-20 Devincent James F Treatment for cocaine abuse
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
GB9420010D0 (en) * 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
ID26346A (id) * 1998-03-31 2000-12-14 Shionogi & Co PROSES PEMBUATAN TURUNAN ASAM 5-HIDROKSIBENZO (b)TIOFEN-3-KARBOKSILAT
AU4100699A (en) 1998-05-28 1999-12-13 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6890951B2 (en) * 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
EP1133299A1 (en) * 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6750235B1 (en) * 1999-09-30 2004-06-15 The General Hospital Corporation Pramipexole as a treatment for cocaine craving
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
KR100712570B1 (ko) * 2001-01-17 2007-05-02 하이디엄, 인크. 알콜 의존성 치료약의 제조에서 플루마제닐의 용도
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CA2436511C (en) * 2001-02-15 2009-08-04 Juan Jose Legarda Ibanez Use of flumazenil to produce a medicament for the treatment of cocaine dependency
US20020150632A1 (en) * 2001-04-12 2002-10-17 Nick Scott Psychonutracological method for craving reduction in humans
FR2827172B1 (fr) * 2001-07-13 2004-07-02 Pf Medicament Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
US20030176456A1 (en) * 2001-12-21 2003-09-18 June Harry L. Methods for reducing alcohol cravings in chronic alcoholics
US6740677B2 (en) * 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids
AU2004216360B2 (en) * 2003-02-27 2009-09-17 Eisai R & D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
CA2526101A1 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
JP2005332453A (ja) * 2004-05-19 2005-12-02 Hitachi Ltd 情報再生装置及び情報再生方法
US20060167723A1 (en) * 2005-01-21 2006-07-27 Berg L M Method of treating dependencies
JP2008538748A (ja) 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物

Also Published As

Publication number Publication date
EP1742639A2 (en) 2007-01-17
AU2006240324B2 (en) 2010-02-25
MX2007012993A (es) 2008-03-11
CA2605918A1 (en) 2006-11-02
NZ562585A (en) 2010-04-30
EP1742639A4 (en) 2008-05-07
CR9444A (es) 2008-02-20
US20050192271A1 (en) 2005-09-01
WO2006115743A3 (en) 2007-06-28
US20090215751A1 (en) 2009-08-27
US7863267B2 (en) 2011-01-04
CN101203225A (zh) 2008-06-18
US20080207599A1 (en) 2008-08-28
ZA200709048B (en) 2008-09-25
NO20075562L (no) 2007-12-07
BRPI0610038A2 (pt) 2016-11-29
AU2006240324A1 (en) 2006-11-02
JP2008536921A (ja) 2008-09-11
RU2007143053A (ru) 2009-05-27
EP1742639B1 (en) 2012-01-04
KR20080004615A (ko) 2008-01-09
WO2006115743A2 (en) 2006-11-02
IL186641A0 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
BRPI0607402A2 (pt) uso de inibidores de pde7 para o tratamento de dor neuropática
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA200901308A1 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
ATE447574T1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
ATE481969T1 (de) Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
DK1660507T3 (da) Proteasominibitorer og metoder til anvendelse heraf
ATE540950T1 (de) Aminocyclohexane als dipeptidylpeptidase-iv- hemmer zur behandlung bzw. prävention von diabetes
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
EA201000584A1 (ru) Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
DE602006012013D1 (de) Proteasom-hemmer und verwendungsverfahren dafür
EA200801164A3 (ru) Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
ZA200709048B (en) Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
DE602005026276D1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
EA200870089A1 (ru) Применение производных бензоконденсированного гетероциклического сульфамида для лечения злоупотребления психоактивным веществом и аддикции
IL186356A0 (en) Method of treating of preventing type-2 diabetes
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
EA201190135A1 (ru) Композиции на основе эмульгированных наркотических веществ для лечения боли при раке
DE602006011959D1 (de) Na+, k+-atpase-expression bei zervixdysplasie und -krebs
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60033569D1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus